Proteintech, a supplier of antibodies and life science research tools, has released Able, an artificial intelligence–based platform designed to streamline antibody selection and experimental planning.
Selecting antibodies that are both target-specific and experimentally validated remains a major challenge for researchers, given the vast number of products available. Able addresses this problem by integrating AI algorithms with Proteintech’s database of antibodies and associated experimental data. The platform provides recommendations tailored to researchers’ stated needs, alongside experimental protocols and relevant literature, with the goal of minimizing time spent on reagent evaluation and planning.
The launch follows Proteintech’s introduction earlier this year of a 3D epitope mapping platform, which combined experimental assays with AI-driven structural modelling to visualize antibody binding sites. That development aimed to reduce uncertainty in antibody design and application, improving reproducibility and precision.
Able represents the next phase in our mission to empower scientists. By combining AI-guided antibody recommendations with experimental guidance, the platform enables researchers to dedicate more time to discovery rather than product selection.
Jason Li, PhD, Chief Executive Officer of Proteintech
Able is freely available for use without subscription on Proteintech’s website.